Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Executive Vice President & CFO | February 10, 2021 | February 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date February 10, 2021 · Filed February 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 215,428 |
Ending reported balance
After 2021-02-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-10 · Tax withholding · Disposed 2,564 · Balance 221,355 F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Row 2 · 2021-02-10 · Tax withholding · Disposed 5,927 · Balance 215,428 F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units.
F2: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2021 Filed Feb 12, 2021 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 5,927 | $25.95 | $153,805.65 |
DisclosureSEC source: 0001192482-21-000147 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,428 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,564 | $25.95 | $66,535.80 |
DisclosureSEC source: 0001192482-21-000147 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,355 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of performance stock units. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 120,000 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001192482-21-000084 · edgar.xml · derivative · entry 3 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-01-19 F3 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2022, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000084 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,919 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 8,161 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:28 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000084 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,758 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:08 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-21-000096 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,919 F2 · price: On January 19, 2021, the Compensation Committee of the Board of Directors of the issuer determined that performance-vesting criteria were met with regard to 8,161 performance share units granted in two prior years. Read SEC document |
| January 19, 2021 Filed Jan 22, 2021 21:08 UTC Amendment | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000096 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,758 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2022, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| August 10, 2020 Filed Aug 12, 2020 20:06 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,515 | $18.89 | $28,618.35 |
DisclosureSEC source: 0001192482-20-000668 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,758 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:32 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 4,025 | $21.62 | $87,020.50 |
DisclosureSEC source: 0001192482-20-000153 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,273 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 31,250 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001192482-20-000136 · edgar.xml · derivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2030-02-05 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 21:09 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000136 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,298 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2021, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 21, 2020 Filed Jan 22, 2020 21:26 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 214 | $21.56 | $4,613.84 |
DisclosureSEC source: 0001192482-20-000042 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,173 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,517 | $11.24 | $17,051.08 |
DisclosureSEC source: 0001192482-19-000335 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,387 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 26, 2019 Filed Aug 13, 2019 20:42 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 797 | $9.04 | $7,204.88 |
DisclosureSEC source: 0001192482-19-000335 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,904 F1 · kind: Shares acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:02 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 181 | $10.35 | $1,873.35 |
DisclosureSEC source: 0001192482-19-000318 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,107 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:59 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,693 | $14.39 | $38,752.27 |
DisclosureSEC source: 0001192482-19-000071 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,288 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 32,000 | $0.00 Strike: $15.90 | $0.00 |
DisclosureSEC source: 0001192482-19-000057 · edgar.xml · derivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2029-01-25 F2 · derivative.exercise_date: Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2020, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 21:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000057 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,981 F1 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2020, and the balance of the restricted stock units vest in equal annual installments over the following three-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vesting date in shares of the issuer's common stock. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 21:13 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 214 | $15.76 | $3,372.64 |
DisclosureSEC source: 0001192482-19-000037 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,981 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 20:07 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 599 | $18.03 | $10,799.97 |
DisclosureSEC source: 0001192482-18-000415 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,195 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 21:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 181 | $20.15 | $3,647.15 |
DisclosureSEC source: 0001192482-18-000380 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,794 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 27, 2018 Filed Aug 6, 2018 21:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 539 | $15.84 | $8,537.76 |
DisclosureSEC source: 0001192482-18-000380 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,975 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 22:25 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 4,900 | $28.35 | $138,915.00 |
DisclosureSEC source: 0001192482-18-000320 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,436 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. F3 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.84 to $28.55, inclusive. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 22:25 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 5,100 | $27.50 | $140,250.00 |
DisclosureSEC source: 0001192482-18-000320 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2018. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.80 to $27.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 21:03 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 1,197 | $21.77 | $26,058.69 |
DisclosureSEC source: 0001192482-18-000098 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,436 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 05, 2018 Filed Feb 6, 2018 21:18 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 214 | $23.38 | $5,003.32 |
DisclosureSEC source: 0001192482-18-000078 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,633 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 00:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 1,044 | $10.17 | $10,617.48 |
DisclosureSEC source: 0001192482-18-000063 · edgar.xml · nonDerivative · entry 3 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,847 F2 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 25, 2018 Filed Jan 30, 2018 00:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 50,000 | $0.00 Strike: $24.35 | $0.00 |
DisclosureSEC source: 0001192482-18-000063 · edgar.xml · derivative · entry 4 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-25 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2019, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. Read SEC document |
| January 25, 2018 Filed Jan 30, 2018 00:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000063 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,803 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2018. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2019, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the reporting person's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| December 14, 2017 Filed Jan 30, 2018 00:38 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-18-000063 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,803 Read SEC document |
| August 04, 2017 Filed Aug 4, 2017 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 200 | $12.39 | $2,478.00 |
DisclosureSEC source: 0001192482-17-000214 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,803 F2 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| July 28, 2017 Filed Aug 4, 2017 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 776 | $10.60 | $8,225.60 |
DisclosureSEC source: 0001192482-17-000214 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,003 F1 · kind: Shares acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:26 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | PurchaseCommon Stock | 10,000 | $9.18 | $91,800.00 |
DisclosureSEC source: 0001192482-17-000127 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,227 Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 20:44 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 388 | $14.95 | $5,800.60 |
DisclosureSEC source: 0001192482-17-000087 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,227 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:53 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 32,500 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · derivative · entry 3 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2027-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:53 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 16,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 2 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,615 F2 · security: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock. Read SEC document |
| January 27, 2017 Filed Feb 14, 2017 22:53 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 1,006 | $10.08 | $10,140.48 |
DisclosureSEC source: 0001192482-17-000039 · edgar.xml · nonDerivative · entry 1 Brannelly Paul · CIK 0001394936 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,365 F1 · kind: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.